A U.S. judge on January 14 barred Martin Shkreli from the pharmaceutical industry for life and ordered him to pay $64.6 million after he famously raised the price of the drug Daraprim and fought to block generic competitors.
If you are not happy with the results below please do another search
50 search results for:
On January 3, 2022, a marvel of intelligence and ingenuity departed from the life science community in the form of Beatrice Mintz, who passed three weeks before her 101st birthday. Born in the Big Apple on January 24, 1921, Dr. Mintz would grow up to become one of the pioneering minds of modern embryology, whose trailblazing research would pave the way for current explorations of genetics.
Emergent BioSolutions came into 2022 after a challenging year that saw the company lose a lucrative contract with the U.S. government following a production mishap that ruined millions of doses of Johnson & Johnson’s COVID-19 vaccine.
After a strong 2021 that included the acquisition of GW Pharmaceuticals, the approval of the acute lymphoblastic leukemia drug Rylaze and the achievement of $3 billion in annual revenue, Jazz Pharmaceuticals set the company’s sights on nearly doubling that return by 2025.
New research out of Harvard University strongly suggests that infection with the Epstein-Barr virus (EBV) is the leading cause of a debilitating disease of the brain and CNS – multiple sclerosis.
Former U.S. Food and Drug Administration Commissioner Robert Califf is one step closer to returning to his old office after the Senate Health, Education, Labor and Pensions Committee advanced his nomination in a 13–8 bipartisan vote.
The next “giant leap” for humans may be a trip to Mars, but having enough oxygen-carrying red blood cells for the journey might present a challenge, new research suggests.
Affini-T Therapeutics, a new cell therapy company launched by researchers from Fred Hutchinson Cancer Center, made its public debut at the 2022 J.P. Morgan Healthcare Conference with a mission to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
The World Health Organization updated WHO’s treatment guidelines for COVID-19 for the eighth time, recommending baricitinib for individuals with severe COVID-19 when used with corticosteroids. In other news, researchers from the Medical University of Bialystok in Poland identified a gene that appears to double the risk of severe COVID-19.
A safety panel of the European drug regulator on January 14 recommended adding a rare spinal inflammation called transverse myelitis as a side effect of AstraZeneca’s COVID-19 vaccine.